One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment

BACKGROUND: The novel coronavirus is still mutating, and the pandemic continues. Meanwhile, many COVID-19 survivors have residual postinfection clinical manifestations. Human umbilical cord mesenchymal stem cells (hUC-MSCs) have been shown to be effective in the early stages of COVID-19. OBJECTIVES:...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Lei, Zheng, You, Cheng, Zhi, Ji, Ningfei, Niu, Changming, Wang, Yan, Huang, Tingrong, Li, Ruyou, Huang, Mao, Chen, Xiaolin, Shu, Lei, Wu, Mingjing, Deng, Kaili, Wei, Jing, Wang, Xueli, Cao, Yang, Yan, Jiaxin, Feng, Ganzhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288258/
https://www.ncbi.nlm.nih.gov/pubmed/35842684
http://dx.doi.org/10.1186/s13287-022-02972-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288258/
https://www.ncbi.nlm.nih.gov/pubmed/35842684
http://dx.doi.org/10.1186/s13287-022-02972-3

Ejemplares similares